LoAc / Mironid - LARVOL DELTA

Navigating the Translation of LoAc Compound Efficacy in ADPKD (KIDNEY WEEK 2024) - "Test groups were compared to groups receiving vehicle alone or tolvaptan. LoAc® compounds suppress cystic disease progression in key translational models of ADPKD and are differentiated from clinically evaluated strategies. Urinary cAMP represents an accessible biomarker of LoAc® compound activity for translation to clinical studies."

Clinical • Autosomal Dominant Polycystic Kidney Disease • Nephrology • Polycystic Kidney Disease • Renal Disease

Targeting cAMP in ADPKD by small molecule activation of long form PDE4 enzymes (ERA-EDTA 2024) - "We have shown that in rat, acute or multiple dosing, of LoAc® compound MR-L22 results in a significant reduction of urinary cAMP and a small, but measurable, increase in urine production and commensurate decrease in urine osmolality. Furthermore, we have demonstrated that significantly reduced urinary and kidney cAMP levels correlate with reductions in TKV, cystic index, Kw/Bw, BUN and urinary NGAL in the Pkd1RC/RC model of ADPKD. In these studies, we have demonstrated beneficial differentiation vs tolvaptan on limiting aquaretic effects but been unable to conclusively demonstrate additive or synergistic effects of MR-L22 combined with tolvaptan due to experimental limitations; Further experiments will be needed to answer this question."

Autosomal Dominant Polycystic Kidney Disease • Nephrology • Polycystic Kidney Disease • Renal Disease